209 related articles for article (PubMed ID: 10582136)
21. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY
Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
Adam M; Ottenjann S; Künzel G; Busch R; Erhardt W; Nieder C; Molls M
Strahlenther Onkol; 2006 Apr; 182(4):231-9. PubMed ID: 16622625
[TBL] [Abstract][Full Text] [Related]
23. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
24. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.
von Pawel J; von Roemeling R; Gatzemeier U; Boyer M; Elisson LO; Clark P; Talbot D; Rey A; Butler TW; Hirsh V; Olver I; Bergman B; Ayoub J; Richardson G; Dunlop D; Arcenas A; Vescio R; Viallet J; Treat J
J Clin Oncol; 2000 Mar; 18(6):1351-9. PubMed ID: 10715308
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway.
Nagasawa H; Mikamo N; Nakajima Y; Matsumoto H; Uto Y; Hori H
Anticancer Res; 2003; 23(6a):4427-34. PubMed ID: 14666730
[TBL] [Abstract][Full Text] [Related]
26. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown JM
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of DNA replication by tirapazamine.
Peters KB; Wang H; Brown JM; Iliakis G
Cancer Res; 2001 Jul; 61(14):5425-31. PubMed ID: 11454687
[TBL] [Abstract][Full Text] [Related]
28. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
29. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
30. Change in oxygenation status in intratumour total and quiescent cells following gamma-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment.
Masunaga S; Ono K; Hori H; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y
Br J Radiol; 2000 Sep; 73(873):978-86. PubMed ID: 11064652
[TBL] [Abstract][Full Text] [Related]
31. Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.
Bishop JF
Lung Cancer; 1995 Jun; 12 Suppl 2():S53-61. PubMed ID: 7551950
[TBL] [Abstract][Full Text] [Related]
32. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
Gandara DR; Lara PN; Goldberg Z; Le QT; Mack PC; Lau DH; Gumerlock PH
Semin Oncol; 2002 Feb; 29(1 Suppl 4):102-9. PubMed ID: 11894020
[TBL] [Abstract][Full Text] [Related]
33. Tirapazamine plus cisplatin and irradiation in a mouse model: improved tumor control at the cost of increased toxicity.
Adam M; Bayer C; Henke J; Grosu A; Molls M; Nieder C
J Cancer Res Clin Oncol; 2008 Feb; 134(2):137-46. PubMed ID: 17622558
[TBL] [Abstract][Full Text] [Related]
34. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
35. Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors.
Maxim PG; Carson JJ; Ning S; Knox SJ; Boyer AL; Hsu CP; Benaron DA; Walleczek J
Radiat Res; 2004 Aug; 162(2):185-93. PubMed ID: 15387146
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
Papadopoulou MV; Ji M; Ji X; Bloomer WD
Cancer Chemother Pharmacol; 2002 Oct; 50(4):291-8. PubMed ID: 12357303
[TBL] [Abstract][Full Text] [Related]
37. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
Delahoussaye YM; Hay MP; Pruijn FB; Denny WA; Brown JM
Biochem Pharmacol; 2003 Jun; 65(11):1807-15. PubMed ID: 12781332
[TBL] [Abstract][Full Text] [Related]
38. Tirapazamine: laboratory data relevant to clinical activity.
Brown JM; Wang LH
Anticancer Drug Des; 1998 Sep; 13(6):529-39. PubMed ID: 9755717
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
